What is the comprehensive management of septic shock?

Complete Management of Septic Shock

Initiate aggressive resuscitation immediately with at least 30 mL/kg crystalloid within 3 hours, start broad-spectrum antibiotics within 1 hour, begin norepinephrine when MAP remains <65 mmHg despite fluids, identify and control the infection source within 12 hours, and escalate to vasopressin then epinephrine if hypotension persists. 1, 2

A. Recognition and Screening

• Screen all acutely ill, high-risk patients for sepsis using a performance improvement program to enable earlier implementation of therapy 1
• Recognize septic shock by persistent hypotension (MAP <65 mmHg) despite adequate fluid resuscitation, serum lactate >2 mmol/L, and need for vasopressor support 3

B. Immediate Diagnostic Workup (Within First Hour)

• Obtain at least 2 sets of blood cultures (aerobic and anaerobic) before antimicrobials—one drawn percutaneously and one through each vascular access device unless recently inserted (<48 hours)—but do not delay antibiotics beyond 45 minutes 1
• Measure baseline serum lactate and repeat within 6 hours if elevated; aim for normalization as a resuscitation endpoint 1, 4, 2
• Perform imaging studies promptly (CT scan) to confirm the infection source and determine if emergent source control is needed 1

C. Antimicrobial Therapy

• Administer IV broad-spectrum antimicrobials within 1 hour of recognizing septic shock—this is the single most time-critical intervention 1, 5
• Select empiric therapy covering all likely pathogens (bacterial, fungal, viral) with adequate tissue penetration to the presumed infection source 1
• Use combination therapy (two different antimicrobial classes) for initial management of septic shock, particularly for neutropenic patients, multidrug-resistant organisms (Acinetobacter, Pseudomonas), respiratory failure with Pseudomonas bacteremia, or bacteremic Streptococcus pneumoniae 1
• Reassess the antimicrobial regimen daily for de-escalation opportunities once susceptibility profiles are known 1
• Discontinue combination therapy within 3–5 days and narrow to single-agent therapy based on culture results 1
• Plan for 7–10 days total duration for most serious infections; extend therapy for slow clinical response, undrainable foci, S. aureus bacteremia, fungal/viral infections, or neutropenia 1
• Use procalcitonin levels to support shortening antimicrobial duration or discontinuing empiric antibiotics in patients with limited clinical evidence of infection 1

D. Source Control

• Identify or exclude an anatomic infection source requiring emergent intervention as rapidly as possible, ideally within 12 hours 1, 2
• Implement source control (drainage, debridement, device removal) as soon as medically and logistically practical after diagnosis 1
• Remove intravascular access devices that are possible infection sources after establishing alternative vascular access 1, 2
• Prefer the least physiologically invasive effective intervention (percutaneous drainage over open surgery when feasible) 2

E. Fluid Resuscitation

Initial Resuscitation (First 3 Hours)

• Administer at least 30 mL/kg of crystalloid within the first 3 hours—this is a minimum target; most patients require additional volume 1, 2, 3, 5, 6
• Use balanced crystalloids (lactated Ringer's or Plasma-Lyte) preferentially over normal saline to reduce hyperchloremic acidosis and acute kidney injury risk 2
• Do not delay fluid resuscitation in patients with chronic heart failure (even with reduced ejection fraction)—the standard 30 mL/kg bolus applies to this population 7

Ongoing Fluid Management

• Continue fluid challenges while hemodynamic parameters improve, using dynamic variables (pulse-pressure variation, stroke-volume variation, passive leg raise) when available, or static signs (arterial pressure, heart rate, mental status, urine output ≥0.5 mL/kg/h, capillary refill, skin perfusion) 1, 2, 7
• Stop fluid administration when tissue perfusion fails to improve, signs of fluid overload develop (rising JVP, new pulmonary crackles, decreasing oxygen saturation, peripheral edema), or hemodynamic parameters stabilize 2
• Add albumin when large volumes of crystalloids (several liters) are required to maintain adequate blood pressure, especially in oncotic deficit or prolonged shock 2, 7
• Avoid hydroxyethyl starch solutions—they increase mortality and acute kidney injury risk 2, 7
• Avoid gelatin solutions when crystalloids are available 2

F. Vasopressor and Inotropic Therapy

Hemodynamic Monitoring

• Place an arterial catheter for continuous blood pressure monitoring as soon as practical after initiating vasopressors 1, 4, 2, 7
• Establish central venous access for norepinephrine administration whenever possible; peripheral administration through a large-bore (≥20-gauge) IV is acceptable if central access is delayed 4, 5

First-Line Vasopressor: Norepinephrine

• Initiate norepinephrine as the mandatory first-line vasopressor when MAP remains <65 mmHg despite adequate fluid resuscitation 1, 4, 2, 7, 3, 5, 6
• Start at 0.02–0.05 µg/kg/min and titrate to achieve MAP ≥65 mmHg 4
• Target MAP of 65 mmHg for most patients; consider 70–85 mmHg in patients with chronic hypertension to reduce need for renal replacement therapy 4, 2
• Do not delay norepinephrine while pursuing excessive fluid resuscitation in severe hypotension—early vasopressor use is appropriate when diastolic pressure is critically low 4

Second-Line Vasopressor: Vasopressin

• Add vasopressin at a fixed dose of 0.03 units/min when norepinephrine reaches 0.1–0.25 µg/kg/min and MAP remains <65 mmHg 4, 2, 5, 6
• Vasopressin must always be added to norepinephrine—never use as monotherapy 4
• Do not exceed 0.03–0.04 units/min except as salvage therapy—higher doses cause cardiac, digital, and splanchnic ischemia without additional hemodynamic benefit 4

Third-Line Vasopressor: Epinephrine

• Add epinephrine starting at 0.05 µg/kg/min (titrate up to 0.3 µg/kg/min) when MAP cannot be achieved with norepinephrine plus vasopressin 4, 5, 6

Inotropic Support: Dobutamine

• Add dobutamine 2.5–20 µg/kg/min when MAP is adequate (≥65 mmHg) but signs of tissue hypoperfusion persist (elevated lactate, low urine output, altered mental status, cold extremities), especially when myocardial dysfunction is evident 1, 4, 2, 7

Agents to Avoid

• Strongly avoid dopamine as first-line therapy—it increases mortality by 11% absolute risk and causes significantly more arrhythmias compared to norepinephrine 4
• Reserve dopamine only for highly selected patients with absolute/relative bradycardia and low arrhythmia risk 1, 4
• Do not use low-dose dopamine for renal protection—it is ineffective and contraindicated (Grade 1A) 1, 4, 2, 7
• Avoid phenylephrine except in three specific situations: norepinephrine-induced serious arrhythmias, documented high cardiac output with persistent hypotension, or salvage therapy after all other agents fail 4

G. Adjunctive Therapies for Refractory Shock

• Consider hydrocortisone 200 mg/day IV for refractory shock unresponsive to vasopressors after ≥4 hours of high-dose therapy 4, 5, 6
• Consider angiotensin II for profound hypotension unresponsive to standard catecholamine vasopressors, especially in vasoplegic shock 4

H. Monitoring and Resuscitation Endpoints

Tissue Perfusion Assessment (Every 2–4 Hours)

• Monitor lactate clearance—obtain baseline and repeat within 6 hours; aim for normalization 1, 4, 2
• Maintain urine output ≥0.5 mL/kg/h 1, 4, 2
• Assess mental status, skin perfusion, and capillary refill regularly 1, 4, 2
• Do not rely solely on MAP—incorporate tissue perfusion markers into decision-making 4

Hemodynamic Parameters

• Use dynamic variables (pulse-pressure variation, stroke-volume variation) over static pressures (CVP) to predict fluid responsiveness 2
• Central venous pressure alone is unreliable for predicting fluid responsiveness, particularly in the 8–12 mmHg range 2

I. Supportive Care

• Initiate mechanical ventilation with tidal volume reduced to 6 mL/kg (from 10 mL/kg) if indicated 6
• Administer heparin for venous thromboembolism prophylaxis 6
• Implement glycemic control 6
• Consider early rehabilitation within 48 hours of ICU admission to improve mobilization without worsening mortality 8

J. Critical Pitfalls to Avoid

• Do not delay antimicrobials beyond 1 hour—every hour of delay increases mortality 1, 5
• Do not withhold the 30 mL/kg fluid bolus in patients with heart failure—this population requires standard resuscitation 7
• Do not exceed vasopressin 0.03–0.04 units/min—higher doses cause end-organ ischemia 4
• Do not use dopamine for renal protection or as first-line vasopressor 1, 4, 2, 7
• Do not delay source control beyond 12 hours when feasible 1, 2
• Do not focus solely on MAP targets—assess tissue perfusion markers 4, 2

K. Vasopressor Weaning Strategy

• Wean norepinephrine first and discontinue vasopressin last—withdrawing vasopressin before norepinephrine causes greater hemodynamic instability 4
• Confirm sustained hemodynamic stability (MAP ≥65 mmHg for ≥2 hours without dose escalation) with adequate tissue perfusion markers before initiating weaning 4
• Reduce norepinephrine gradually (decrements of 0.02–0.05 µg/kg/min) while maintaining vasopressin at 0.03 units/min 4
• Discontinue vasopressin abruptly once norepinephrine is tapered to low doses (<0.1 µg/kg/min) and hemodynamics remain stable 4